Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHA:688621)
China flag China · Delayed Price · Currency is CNY
69.78
+0.78 (1.13%)
Sep 10, 2026, 2:09 PM CST

SHA:688621 Balance Sheet

Millions CNY. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
464.94462.17565.56690.93608.93490.25
Short-Term Investments
-8020---
Trading Asset Securities
4075303013.11157.6
Cash & Short-Term Investments
504.94617.17615.56720.93622.04647.85
Cash Growth
-27.30%0.26%-14.62%15.90%-3.98%492.70%
Accounts Receivable
927.18935.3774.96555.83362.73239.2
Other Receivables
8.246.6510.1611.2116.1712
Receivables
935.42941.95785.12567.04378.9251.21
Inventory
13.3414.0315.0514.4112.547.84
Prepaid Expenses
-----1.9
Other Current Assets
214.25167.4798.7654.7626.4832.99
Total Current Assets
1,6681,7411,5141,3571,040941.79
Property, Plant & Equipment
165.53177.91211.61220.26197.02161.05
Long-Term Investments
221.07179.29115.69100.7594.7540
Goodwill
21.2620.5126.0626.0626.0626.06
Other Intangible Assets
5.14.735.415.394.23.32
Long-Term Deferred Tax Assets
134.34102.2764.0438.9316.695.03
Long-Term Deferred Charges
31.5530.6448.2864.1976.2533.41
Other Long-Term Assets
17.0728.821.7350.318.7831.99
Total Assets
2,2642,2851,9871,8631,4641,243

Liabilities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Accounts Payable
53.3649.0930.6849.1222.1312.52
Accrued Expenses
21.9142.0253.6347.4437.2927.33
Short-Term Debt
580.08499.13309.39383.93201.17138.01
Current Portion of Long-Term Debt
32.6719.219.3---
Current Portion of Leases
-17.6324.7822.122.5418.98
Current Income Taxes Payable
19.1231.146.624.9216.9311.42
Current Unearned Revenue
256.51299.15321.43220.83205.85199.85
Other Current Liabilities
10.711.2812.7612.8812.279.72
Total Current Liabilities
974.35968.65778.56761.21518.19417.83
Long-Term Debt
38.44867.2---
Long-Term Leases
31.5529.7535.1240.6233.8449.72
Long-Term Unearned Revenue
3.873.572.523.592.835.46
Long-Term Deferred Tax Liabilities
0.080.051.250.350.24-
Other Long-Term Liabilities
-1.28----
Total Liabilities
1,0481,051884.65805.76555.1473.01

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Common Stock
1121121121128080
Additional Paid-In Capital
435.5406.54375.86474.17499.85499.85
Retained Earnings
753.99798.83612.78453.85317.09182.1
Treasury Stock
-100-100----
Total Common Equity
1,2011,2171,1011,040896.93761.95
Minority Interest
14.1316.122.0117.2511.677.69
Shareholders' Equity
1,2161,2331,1031,057908.6769.64
Total Liabilities & Equity
2,2642,2851,9871,8631,4641,243

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Total Debt
682.7613.71455.79446.65257.55206.71
Net Cash (Debt)
-177.763.45159.77274.28364.48441.14
Net Cash Growth
--97.84%-41.75%-24.75%-17.38%414.12%
Net Cash Per Share
-1.620.031.422.453.264.50
Filing Date Shares Outstanding
107.2109.28112112112112
Total Common Shares Outstanding
107.2109.28112112112112
Working Capital
693.59771.97735.93595.93521.77523.96
Book Value Per Share
11.2111.149.839.298.016.80
Tangible Book Value
1,1751,1921,0691,009866.68732.57
Tangible Book Value Per Share
10.9610.919.559.017.746.54
Machinery
-261.43256.34232.62195.9124.14
Construction In Progress
-----3.4